Figure 7

LncRNA RP11-86H7.1 acts as a ceRNA by sponging miR-9-5p to upregulate their common target, NFKB1 and promote inflammatory response by the gain and loss of function assay. (A) ELISA analysis of IL-6, IL-8, and TNF-α levels in 16HBE cells co-transfected with lncRNA RP11-86H7.1 or miR-9-5p mimic. (B, C) Q-PCR analysis of the mRNA expression levels of IL-6, IL-8, TNF-α, lncRNA RP11-86H7.1, NFKB1, IκBα, and p65 in 16HBE cells co-transfected with lncRNA RP11-86H7.1 or miR-9-5p mimic. (D) Western blotting analysis of the protein levels of NFKB1, p-IκBα and p-p65 in 16HBE cells co-transfected with lncRNA RP11-86H7.1 or miR-9-5p mimic. GAPDH was used as an internal control. (E) ELISA analysis of IL-6, IL-8, and TNF-α levels 16HBE cells co-transfected with lncRNA RP11-86H7.1 knockdown or miR-9-5p inhibitor. (F, G) Q-PCR analysis of the mRNA expression levels of IL-6, IL-8, TNF-α, lncRNA RP11-86H7.1, NFKB1, IκBα, and p65 in 16HBE cells co-transfected with lncRNA RP11-86H7.1 knockdown or miR-9-5p inhibitor. (H) Western blot analysis of the protein levels of NFKB1, p-IκBα and p-p65 in 16HBE cells co-transfected with lncRNA RP11-86H7.1 knockdown or miR-9-5p inhibitor. GAPDH was used as an internal control. The data are shown as the means ± standard deviations (n = 3). The statistical significance of the data was assessed by Student’s t test. *P < 0.05, **P < 0.01.